Source: International Congress 2019 – Clinical aspects of airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
H. Ates (Ankara, Turkey), K. Aksu (Ankara, Turkey), Ö. Özdedeoglu (Ankara, Turkey), B. Basa Akdogan (Ankara, Turkey), I. Koca Kalkan (Ankara, Turkey), G. Köycü Buhari (Ankara, Turkey), F. Öner Erkekol (Ankara, Turkey). Cost analysis for patients with severe asthma receiving omalizumab treatment. 2756

Member's Comments

No comment yet.

Related content which might interest you: Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004 Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Cost of asthma rescue/acute and allergy medications among asthmatic patients on controller therapy Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations Source: Eur Respir J 2007; 30: Suppl. 51, 72s Year: 2007 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Cost implications for the introduction of omalizumab in to the management of severe chronic asthma in children Source: Eur Respir J 2006; 28: Suppl. 50, 481s Year: 2006 The use of omalizumab in the management of severe chronic paediatric asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001